Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peter Moosmann
• Collaborator: Kantonsspital Aarau
• Treatments: Bendamustine Hydrochloride; Bortezomib

Criteria

Inclusion Criteria:

• Symptomatic recurrent or refractory indolent NHL or B-CLL

• Adequate organ and bone marrow function

• Karnofsky greater than 50%

Exclusion Criteria:

• Candidates for autologous stem cell transplantation

• Secondary high grade lymphoma

• Concurrent severe medical condition